Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Link

Linee Guida ATP III
pdf

Krolewski AS, Warram JH, Valsania P, et al.
Evolving natural history of coronary artery disease in diabetes mellitus.
Am J Med 90: 56S-61S, 1991
Abstract

Sprafka JM, Burke GL, Folsom AR, et al.
Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. The Minnesota Heart Survey.
Diabetes Care 14: 537-543, 1991
Abstract

Stamler J, Vaccaro O, Neaton JD, Wentworth D.
Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.
Diabetes Care 16: 434-444, 1993
Abstract

Turner RC, Millns H, Neil HA, et al.
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23).
BMJ 316: 823-828, 1998
Link

Wild S, Roglic G, Green A, et al.
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053, 2004
Link

Brunzell JD, Davidson M, Furberg CD, et al.
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.
Diabetes Care 31: 811-822, 2008
Link

Volpe M, Erhardt LR, Williams B.
Managing cardiovascular risk: the need for change.
J Hum Hypertens 22: 154-157, 2008
Abstract

Stamler J, Vaccaro O, Neaton JD, Wentworth D.
Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.
Diabetes Care 16: 434-444, 1993
Abstract

Turner RC, Millns H, Neil HA, et al.
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23).
BMJ 316: 823-828, 1998
Link

Grundy SM, Cleeman JI, Merz CN, et al.
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Circulation 110: 227-239, 2004.
Link

Marshall G, McDougall C, Brady A, Fisher M.
Should all diabetic patients receive a statin? Results from recent trials.
Br J Cardiol 11: 455-460, 2004
Abstract

O'Keefe JH Jr, Cordain L, Harris WH, et al.
Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.
J Am Coll Cardiol 43: 2142-2146, 2004
Abstract

Costa J, Borges M, David C, Vaz Carneiro A.
Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials.
BMJ 332: 1115-1124, 2006
Link

Jacobson TA.
The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?
Mayo Clin Proc 81:1225-1231, 2006
Link

Cholesterol Treatment Trialists' (CTT) Collaborators, et al.
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
Lancet 371: 117-125, 2008
Abstract

Ridker PM, Danielson E, Fonseca FA, et al.
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
N Engl J Med 359: 2195-2207, 2008
Link

Athyros VG, Papageorgiou AA, Athyrou VV, et al.
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
Diabetes Care 25: 1198-1202, 2002
Link

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
Circulation 106: 3143-3421, 2002
Link


Jones PH, Davidson MH, Stein EA, et al.
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Am J Cardiol 92:152-160, 2003
Abstract

Grundy SM, Cleeman JI, Merz CN, et al.
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Circulation 110: 227-239, 2004
Link

Baigent C, Keech A, Kearney PM, et al.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Lancet 366: 1267-1278, 2005
Abstract

Chapman J.
Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia.
Eur Heart J 7(suppl F): F56-F62, 2005
Link

Davidson MH.
Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
Am J Cardiol 96: 3K-13K, 2005
Abstract

Farnier M, Freeman MW, Macdonell G, et al.
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
Eur Heart J 26: 897-905, 2005
Link

Keech A, Simes RJ, Barter P, et al.
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Lancet 366: 1849-1861, 2005
Abstract

LaRosa JC, Grundy SM, Waters DD, et al.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
N Engl J Med 352: 1425-1435, 2005
Link

Costa J, Borges M, David C, Vaz Carneiro A.
Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials.
BMJ 332: 1115-1124, 2006
Link

ACCORD Study Group, Buse JB, Bigger JT, et al.
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.
Am J Cardiol 99(12A): 21i-33i, 2007
Abstract

Barter P, Gotto AM, LaRosa JC, et al.
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
N Engl J Med 357:1301-1310, 2007
Link

Farnier M, Roth E, Gil-Extremera B, et al.
Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
Am Heart J 153: 335 e1-8, 2007.
Abstract

Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.
European guidelines on cardiovascular disease prevention in clinical practice: executive summary.
Eur Heart J 28: 2375-2414, 2007
Link

Scheen AJ, Van Gaal LF.
Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.
Eur Heart J 28: 1401-1402, 2007
Link

American Diabetes Association.
Standards of Medical Care in Diabetes 2008.
Diabetes Care 31: S12-S54, 2008
Link

Brown BG, Zhao XQ.
Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
Am J Cardiol 101: 58B-62B, 2008
Abstract

Cholesterol Treatment Trialists' (CTT) Collaborators, et al.
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
Lancet 371: 117-125, 2008.
Abstract

Holoshitz N, Alsheikh-Ali AA, Karas RH.
Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.
Am J Cardiol 101: 95-97, 2008
Abstract

Miller M, Cannon CP, Murphy SA, et al.
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
J Am Coll Cardiol 51: 724-730, 2008
Link

Scott R, O'Brien R, Fulcher G, et al.
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Diabetes Care 32: 493-498, 2009
Link

Taylor AJ, Villines TC, Stanek EJ, et al.
Extended-release niacin or ezetimibe and carotid intima-media thickness.
N Engl J Med 361: 2113-2122, 2009
Abstract

Kannel WB.
Potency of vascular risk factors as the basis for antihypertensive therapy.
Eur Heart J 13 Suppl G:34-42, 1992
Abstract

Pearson TA, Laurora I, Chu H, Kafonek S.
The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.
Arch Intern Med 160: 459-467, 2000
Link

Gaede P, Vedel P, Larsen N, et al.
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
N Engl J Med 348: 383-393, 2003
Link

Gaede P, Pedersen O.
Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis.
Diabetes 53 Suppl 3: S39-47, 2004
Link

Van Ganse E, Laforest L, Alemao E, et al.
Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.
Curr Med Res Opin 21: 1389-1399, 2005
Abstract

AMD, SID, Diabete Italia.
Standard italiani per la cura del diabete mellito. Linee guida e raccomandazioni, 2007
Link

Mansia G, De Backer G, Dominiczak A, et al.
2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
Blood Press 16:135-232, 2007
Abstract